N-[5-(6-aminopyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]-4,4,4-trifluoro-2-methylbutanamide | 1444302-90-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[5-(6-aminopyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]-4,4,4-trifluoro-2-methylbutanamide
• CAS: 1444302-90-2
• 化学式: C₁₄H₁₅F₃N₄OS
• 分子量: 344.361
• InChiKey: IIFUCWPNUMIYRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  C₁₄H₁₈N₄O₂S 在 盐酸 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 N-[5-(6-aminopyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]-4,4,4-trifluoro-2-methylbutanamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus

  摘要：

  We describe here the design, synthesis and biological evaluation of antiviral compounds acting against human rhinovirus (HRV). A series of aminothiazoles demonstrated pan-activity against the HRV genotypes screened and productive structure-activity relationships. A comprehensive investigational library was designed and performed allowing the identification of potent compounds with lower molecular weight and improved ADME profile. 31d-1, 31d-2, 31f showed good exposures in CD-1 mice. The mechanism of action was discovered to be a host target: the lipid kinase phosphatidylinositol 4-kinase III beta (PI4KIII beta). The identification of the pan-HRV active compound 31f combined with a structurally distinct literature compound T-00127-HEV1 allowed the assessment of target related tolerability of inhibiting this kinase for a short period of time in order to prevent HRV replication. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.077

文献信息

• Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus
  作者：Anne Décor、Chantal Grand-Maître、Oliver Hucke、Jeff O’Meara、Cyrille Kuhn、Léa Constantineau -Forget、Christian Brochu、Eric Malenfant、Mégan Bertrand-Laperle、Josée Bordeleau、Elise Ghiro、Marc Pesant、Gulrez Fazal、Vida Gorys、Michael Little、Colette Boucher、Sylvain Bordeleau、Pascal Turcotte、Tim Guo、Michel Garneau、Catherine Spickler、Annick Gauthier

  DOI：10.1016/j.bmcl.2013.04.077

  日期：2013.7

  We describe here the design, synthesis and biological evaluation of antiviral compounds acting against human rhinovirus (HRV). A series of aminothiazoles demonstrated pan-activity against the HRV genotypes screened and productive structure-activity relationships. A comprehensive investigational library was designed and performed allowing the identification of potent compounds with lower molecular weight and improved ADME profile. 31d-1, 31d-2, 31f showed good exposures in CD-1 mice. The mechanism of action was discovered to be a host target: the lipid kinase phosphatidylinositol 4-kinase III beta (PI4KIII beta). The identification of the pan-HRV active compound 31f combined with a structurally distinct literature compound T-00127-HEV1 allowed the assessment of target related tolerability of inhibiting this kinase for a short period of time in order to prevent HRV replication. (c) 2013 Elsevier Ltd. All rights reserved.